Canton Barry has disclosed several transactions involving Class A common stock in a recent SEC filing, which could have implications for both the individual and the broader market.
The filing, made on October 21, 2026, details Barry's activities related to Ginkgo Bioworks Holdings, Inc., a company known for its work in the biological products sector. Ginkgo Bioworks, trading under the symbol DNA, focuses on developing custom microbes for various applications.
Background
Canton Barry is identified as a significant shareholder in Ginkgo Bioworks, holding a ten percent stake in the company. The recent filing falls under the SEC's reporting requirements for insiders and significant shareholders. Ginkgo Bioworks is classified under the SIC code 2836, which pertains to biological products (no diagnostic substances).
What the Filing Says
The SEC filing reveals that Barry engaged in multiple transactions involving shares of Ginkgo Bioworks. Specifically, on October 16, Barry acquired a total of 63,043 shares through various transactions, including restricted stock units. Additionally, on October 19, Barry sold 41,172 shares to cover tax obligations related to the vesting of restricted stock.
"Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person," the filing states.
Impact
These transactions may affect shareholder perceptions of Ginkgo Bioworks, as they reflect Barry's ongoing confidence in the company's future. Barry's actions could also influence other investors and stakeholders in the biological products industry, prompting them to reassess their positions.
What's Next
The filing does not say what happens next regarding Barry's future transactions or any potential changes in ownership structure.
For further details, refer to the SEC filing under accession number 0001628280-26-066705.